Impact of Matrix Metalloproteinase 9 on COPD Development in Polish Patients: Genetic Polymorphism, Protein Level, and Their Relationship with Lung Function

Table 5

Relationships between FEV₁% and FEV₁/FVC scores and proteins levels in COPD patient and controls groups.

	Parameters relationship		Protein concentrations
			COPD patients			Controls
			MMP-9; ng/ml	MMP-9/TIMP1; pg/ml	MMP-9/TIMP2; ng/ml	MMP-9; ng/ml	MMP-9/TIMP1; pg/ml	MMP-9/TIMP2; ng/ml
Lung function	FEV1 [% predicted]	β	-0.06^1	-0.01	0.01	-0.86^3	0.01	-0.03
		p	0.04	0.30	0.35	0.04	0.24	0.07
	FEV1/FVC [% predicted]	β	-0.04^2	0.006^2	0.005	0.02	-0.01^4	-2.50^4
		p	0.04	0.04	0.72	0.38	0.04	0.04

COPD, chronic obstructive pulmonary disease groups; FEV₁, forced expiratory volume in 1 second; FEV₁/FVC, Tiffeneau-Pinelli index – ratio of forced expiratory volume in 1 second and forced vital capacity; β, coefficients of the regression; ¹, R² = 0.91, estimated FEV₁% = 62.20 - 0.06MMP-9; ², R² = 0.92, estimated FEV₁/FVC = 44.65 + 0.0006MMP-9/TIMP1 - 0.04MMP-9; ³, R² = 0.89, estimated FEV₁% = 113,42 -0.86MMP-9; ⁴, R² = 0.91, estimated FEV₁/FVC = 81.13 - 0.01MMP-9/TIMP1 - 2.50MMP-9/TIMP2; significant data were bolded.